Supreme Court Temporarily Restores Nationwide Access To Abortion Pill

Update (05/04/2026): The U.S. Supreme Court on Monday issued a temporary order that restores full nationwide access to the abortion medication mifepristone, including through mail-order, telehealth prescriptions, and certified pharmacies, until at least May 11.

The emergency ruling pauses a May 1 decision by the conservative 5th U.S. Circuit Court of Appeals that had reinstated a nationwide requirement for in-person dispensing only. That lower-court order had threatened to sharply restrict medication abortion access across the country, even in states where abortion remains legal.

The USSC administrative stay came in response to emergency applications filed Saturday by mifepristone manufacturers Danco Laboratories and GenBioPro. The companies argued the 5th Circuit ruling would cause “immediate confusion,” “regulatory chaos,” and irreparable harm to patients and providers. Justice Samuel Alito, who handles emergency matters from the 5th Circuit, referred the matter to the full Court.

Background

Mifepristone, used in combination with misoprostol, accounts for approximately 60–70% of abortions in the United States and is also used for early miscarriage care. The FDA first approved the drug in 2000 and expanded access in 2016 and 2021, eventually allowing telehealth and mail delivery without an in-person visit requirement beginning in 2023.

In June 2024, the Supreme Court unanimously rejected a previous challenge to the FDA’s rules, ruling that anti-abortion physicians lacked legal standing to sue. The new litigation was brought by Louisiana, which claimed standing as a state harmed by the federal regulations.

What’s Next

The Supreme Court’s order maintains the status quo while the justices consider the manufacturers’ request for a longer stay or further review. A decision on whether to extend the relief beyond May 11 is expected in the coming days or weeks. The case could eventually return to the high court for full briefing and argument on the merits.

The temporary restoration prevents an immediate nationwide disruption to medication abortion services at a time when the method has become the dominant form of abortion care following the 2022 Dobbs decision that overturned Roe v. Wade.

Advocates on both sides are closely watching for further developments. Reproductive health groups welcomed the pause, while opponents of expanded access expressed disappointment that the 5th Circuit’s restrictions were not allowed to take effect immediately.

The ruling marks the latest chapter in a years-long legal battle over one of the most widely used medications in reproductive health care.

* * *

Authored by Jacki Thrapp via The Epoch Times,

Americans won’t be able to receive abortion drug mifepristone in the mail, according to a temporary ruling by the U.S. Fifth Circuit Court on May 1.

“FDA conceded it had failed to adequately study whether remotely prescribing mifepristone is safe,” the three-judge panel in New Orleans ruled on Friday.

The decision will block the drug from being shipped via mail until the Food and Drug Administration (FDA) can ensure the drugs are “safe and effective” before they can be marketed in the United States.

Mifepristone, often called “the abortion pill,” is part of a two-drug regimen which allows a woman “to end a pregnancy up to 70 days into gestation,” according to Johns Hopkins University.

The FDA first approved mifepristone in 2000, but doctors were only allowed to prescribe it after three in-person visits.

The procedure changed in 2023 after the Biden administration expanded access to “medication abortion,” which provided a pathway for patients to avoid an in-person visit to the doctor and, instead, order the drug online to be shipped to their house.

The state of Louisiana challenged the rule in 2025, arguing the justification for allowing this was based on “flawed or nonexistent data.”

Louisiana alleged the medication “resulted in numerous illegal abortions” in the state and it also made women pay “thousands in Medicaid bills” for being harmed by mifepristone.

Louisiana Attorney General Liz Murrill called Friday’s decision a “victory for life!”

“The Biden abortion cartel facilitated the deaths of thousands of Louisiana babies (and millions in other states) through illegal mail-order abortion pills. Today, that nightmare is over, thanks to the hard work of my office and our friends at Alliance Defending Freedom,” Murrill wrote.

“I look forward to continuing to defend women and babies as this case continues.”

A bill to ban mifepristone was introduced by Sen. Josh Hawley (R-Mo.) in March.

“The science is clear: The chemical abortion drug is inherently dangerous to women and prone to abuse. Yet major companies like Danco Laboratories are making billions off it,” Hawley said.

Hawley’s bill would also allow women to sue manufacturers for damages if they are harmed by the chemical abortion.

Rep. Delia C. Ramirez (D-Ill.) criticized the federal court decision on social media.

“Mifepristone is safe and reliable,” Ramirez wrote in an X post on Friday.

“IT SAVES LIVES.
 Extremist attempts to control our bodies and restrict our choices make women less safe. The right to make decisions about our bodies and our healthcare are OURS. They don’t belong in the hands of judges or politicians.”